PTE PolarityTE, Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

Settings

PTE [NASD]

PolarityTE, Inc.

Healthcare | Biotechnology | USA

statements

Index	-	P/E	-	EPS (ttm)	-1.69	Insider Own	25.20%	Shs Outstand	38.76M	Perf Week	-19.53%
Market Cap	27.71M	Forward P/E	-	EPS next Y	-0.81	Insider Trans	-0.93%	Shs Float	25.34M	Perf Month	-32.87%
Income	-53.90M	PEG	-	EPS next Q	-0.19	Inst Own	23.30%	Short Float	9.51%	Perf Quarter	-47.17%
Sales	8.00M	P/S	3.46	EPS this Y	-329.30%	Inst Trans	-0.19%	Short Ratio	2.71	Perf Half Y	-37.87%
Book/sh	0.63	P/B	1.07	EPS next Y	15.60%	ROA	-99.60%	Target Price	-	Perf Year	-78.42%
Cash/sh	0.56	P/C	1.19	EPS next 5Y	15.00%	ROE	-160.20%	52W Range	0.55 - 4.60	Perf YTD	-74.19%
Dividend	-	P/FCF	-	EPS past 5Y	5.60%	ROI	-226.70%	52W High	-85.76%	Beta	1.41
Dividend %	-	Quick Ratio	3.10	Sales past 5Y	-3.30%	Gross Margin	59.90%	52W Low	18.46%	ATR	0.11
Employees	153	Current Ratio	3.20	Sales Q/Q	135.70%	Oper. Margin	-	RSI (14)	32.05	Volatility	15.08% 11.23%
Optionable	Yes	Debt/Eq	0.21	EPS Q/Q	79.00%	Profit Margin	-	Rel Volume	4.56	Prev Close	0.67
Shortable	Yes	LT Debt/Eq	0.11	Earnings	-	Payout	-	Avg Volume	889.54K	Price	0.66
Recom	2.40	SMA20	-26.53%	SMA50	-33.74%	SMA200	-44.17%	Volume	3,511,104	Change	-2.37%

May-01-20

Downgrade

Oppenheimer

Outperform → Perform

Nov-11-19

Resumed

Cantor Fitzgerald

Overweight

$50 → $13

Jul-08-19

Initiated

H.C. Wainwright

Buy

Mar-21-19

Initiated

Evercore ISI

Outperform

$26

Jan-28-19

Initiated

Northland Capital

Outperform

$50

Jan-28-19

Initiated

National Securities

Sell

Dec-20-18

Initiated

Piper Jaffray

Overweight

Nov-24-20 08:00AM	PolarityTE Announces Dismissal of Securities Class Action Complaint with Prejudice Business Wire
Nov-09-20 07:24AM	Recap: PolarityTE Q3 Earnings Benzinga -15.37%
07:00AM	PolarityTE Reports Third Quarter 2020 Results Business Wire
Nov-02-20 08:00AM	PolarityTE Announces Successful Completion of Initial Pre-IND Interaction with U.S. Food and Drug Administration for SkinTE® Business Wire
Oct-26-20 08:00AM	PolarityTE to Report Third Quarter 2020 Financial Results on November 9, 2020 Business Wire +13.06%
Sep-29-20 08:00AM	PolarityTE Announces Termination of Shareholder Rights Plan Business Wire
Sep-21-20 08:00AM	PolarityTE Receives NIH Grant for a Point-of-Care Device to Treat Chronic Wounds Business Wire
Sep-16-20 08:00AM	SkinTE Health EconomicsDFU Interim Analysis Data Demonstrates Potential for Cost Savings and Improved Wound Closure Business Wire
Sep-14-20 08:00AM	PolarityTE Expects Third Quarter Revenue to Meet or Exceed High-End of Guidance Business Wire
Sep-10-20 08:00AM	PolarityTE to Present at H.C. Wainwright 22nd Annual Global Investment Conference and Cantor Virtual Global Healthcare Conference Business Wire
Sep-08-20 08:00AM	PolarityTE Announces Strategic Partnership with Co-Diagnostics to Expand COVID-19 Testing Platform Business Wire +13.46%
08:00AM	Co-Diagnostics, Inc. Enters into Agreement with Arches Research to Expand COVID-19 Testing Services PR Newswire
Aug-06-20 07:00AM	PolarityTE Reports Second Quarter 2020 Results Business Wire
Jul-30-20 08:00AM	PolarityTE Announces the Addition of Clinical Development and Regulatory Affairs Executive Jessica Shen, MD, MS to Board of Directors Business Wire
Jul-29-20 08:00AM	PolarityTE to Report Second Quarter 2020 Financial Results on August 6, 2020 Business Wire -5.73%
Jul-24-20 08:00AM	PolarityTE Announces Positive Top-Line Data from Interim Analysis of SkinTE Diabetic Foot Ulcer Trial Business Wire +10.56%
Jul-20-20 08:00AM	PolarityTE Announces Interim Data from Diabetic Foot Ulcer Trial will be Presented at Symposium on Advanced Wound Care to be Held July 24-26, 2020 Business Wire +27.59%
Jul-05-20 08:50PM	Should You Buy PolarityTE, Inc. (PTE)? Insider Monkey
Jun-10-20 07:52AM	Rising P/E: An Overlooked Trick to Pick 5 Winning Stocks Zacks +27.93%
Jun-01-20 08:00AM	PolarityTETwo Peer-Reviewed Manuscripts Published on SkinTE Business Wire
May-27-20 11:29AM	Verscend Holding Corp. -- Moody's announces completion of a periodic review of ratings of Verscend Holding Corp. Moody's +14.52%
May-11-20 07:00AM	PolarityTE Reports First Quarter 2020 Results Business Wire
Apr-30-20 04:15PM	PolarityTE Provides Update on Corporate Strategy and Regulatory Pathway for SkinTE Business Wire -5.50%
Apr-21-20 08:00AM	PolarityTE Provides Corporate Update Related to COVID-19 and Announces Preliminary First Quarter Results Business Wire -7.96%
Apr-17-20 09:01AM	Do Options Traders Know Something About PolarityTE (PTE) Stock We Don't? Zacks +5.02%
Apr-13-20 08:00AM	PolarityTE Announces Data from Head-to-Head Burn Study Demonstrating Graft Take and Wound Closure with SkinTE Treatment Business Wire +6.72%
Apr-08-20 08:00AM	PolarityTE Announces Conclusion of SEC Investigation Business Wire +11.17%
Apr-06-20 08:00AM	PolarityTE Announces the Addition of Audit Executive Chris Nolet to Board of Directors Business Wire +5.54%
Apr-01-20 08:00AM	PolarityTE Announces Appointment of David Seaburg as CEO and Restructuring of Executive Team Business Wire -12.75%
Mar-15-20 09:26AM	Earnings Release: Here's Why Analysts Cut Their PolarityTE, Inc. Price Target To US$10.17 Simply Wall St.
Mar-12-20 07:00AM	PolarityTE Reports Fiscal Year 2019 Financial Results Business Wire -7.48%
Mar-05-20 08:00AM	PolarityTE to Attend the Oppenheimer 30th Annual Healthcare Conference Business Wire
Mar-03-20 08:00AM	PolarityTE to Report Fiscal Year 2019 Financial Results on March 12, 2020 Business Wire
Feb-18-20 06:38PM	Bragar Eagel & Squire is Investigating Certain Officers and Directors of PolarityTE, comScore, AMC, and Conagra Brands and Encourages Investors to Contact the Firm GlobeNewswire -5.92%
Feb-12-20 09:24AM	PolarityTE's stock loses nearly half its value after public offering of stocks, warrants MarketWatch -47.17%
09:00AM	PolarityTE Announces Pricing of Public Offering of Common Stock and Warrants Business Wire
Feb-11-20 04:01PM	PolarityTE Announces Public Offering of Common Stock and Warrants Business Wire
Dec-19-19 06:29PM	Hedge Funds Are Crazy About PolarityTE, Inc. (PTE) Insider Monkey
Dec-18-19 08:00AM	PolarityTE to Participate in Corporate Access Event in San Francisco, January 13-15, 2020 Business Wire
Dec-12-19 09:11AM	Is the Options Market Predicting a Spike in PolarityTE (PTE) Stock? Zacks
Dec-10-19 08:00AM	PolarityTE Builds Patent Portfolio with New International Patent Grants Business Wire
Dec-06-19 08:00AM	12 Biotech Stocks Primed For A Short Squeeze Benzinga +9.27%
Dec-05-19 08:00AM	PolarityTE Announces Equity Purchase Agreement for up to $25 Million with Keystone Capital Partners Business Wire -12.79%
Nov-28-19 09:42AM	Here's Why We're A Bit Worried About PolarityTE's (NASDAQ:PTE) Cash Burn Situation Simply Wall St.
Nov-27-19 08:00AM	PolarityTE to Attend Evercore ISI 2nd Annual HealthCONx Conference and Piper Jaffray 31st Annual Healthcare Conference TEST Business Wire Releases
08:00AM	PolarityTE to Attend Evercore ISI 2nd Annual HealthCONx Conference and Piper Jaffray 31st Annual Healthcare Conference Business Wire
Nov-19-19 04:55PM	SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating PolarityTE, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire
Nov-12-19 04:05PM	PolarityTE Reports Third Calendar Quarter 2019 Results Business Wire -11.55%
Nov-07-19 04:01PM	PolarityTE Adopts Short-Term Shareholder Rights Plan Business Wire
Oct-24-19 08:00AM	PolarityTE to Report Calendar Third Quarter Financial Results on November 12, 2019 Business Wire -7.93%
Oct-14-19 03:36PM	PolarityTE, Inc. (NASDAQ:PTE): What Does Its Beta Value Mean For Your Portfolio? Simply Wall St.
08:00AM	PolarityTE Announces Positive Pilot Study Data of SkinTE as a Treatment for Venous Stasis Leg Ulcers Business Wire
Oct-06-19 10:00AM	Bragar Eagel & Squire is Investigating Certain Officers and Directors of National General Holdings, Natural Health Trends, Omnicell, and Polarity TE and Encourages Investors to Contact the Firm GlobeNewswire
Oct-03-19 08:00AM	SkinTE Data to be Presented at the 19th Annual Diabetic Foot Global Conference Business Wire
Sep-26-19 08:00AM	PolarityTE Selected to Present at 2019 Cell & Gene Meeting on the Mesa Business Wire -8.98%
Sep-23-19 08:00AM	PolarityTE Announces Positive Data Showing SkinTE Regenerated Full-Thickness Skin in Difficult-to-Treat Wounds Business Wire +5.78%
Sep-18-19 08:00AM	PolarityTE to Attend the 2019 Cantor Global Healthcare Conference Business Wire
Sep-16-19 08:00AM	SkinTE Data Including Final Pilot Study Data Readout to be Presented at the Symposium on Advanced Wound Care Fall Meeting Business Wire
Sep-09-19 08:00AM	SkinTE Data to be Presented at the American Society of Plastic Surgeons 88th Annual Scientific Meeting PR Newswire +5.44%
Sep-04-19 08:00AM	PolarityTE Appoints Peter Cohen as Chairman of the Board PR Newswire +8.89%
Aug-28-19 08:00AM	PolarityTE to Attend H.C. Wainwright 21st Annual Healthcare Conference and Morgan Stanley 17th Annual Global Healthcare Conference PR Newswire +18.08%
Aug-20-19 01:43PM	Introducing PolarityTE (NASDAQ:PTE), The Stock That Tanked 80% Simply Wall St.
12:55PM	PolarityTE Granted Canadian Patent PR Newswire
Aug-16-19 08:00AM	PolarityTE to Present at Military Health System Research Symposium on Platform Technology for Treatment of Traumatic and Chronic Wounds PR Newswire
Aug-08-19 07:00AM	PolarityTE Reports Second Calendar Quarter 2019 Results PR Newswire +19.44%
Jul-25-19 08:00AM	PolarityTE to Report Calendar Second Quarter Financial Results on August 8, 2019 PR Newswire
Jul-24-19 09:35AM	PolarityTE Enters Oversold Territory Zacks
Jun-29-19 07:17PM	Is PolarityTE, Inc. (PTE) A Good Stock To Buy ? Insider Monkey
Jun-19-19 12:30PM	What Type Of Shareholder Owns PolarityTE, Inc.'s (NASDAQ:PTE)? Simply Wall St.
Jun-12-19 11:49AM	Weekly CFO Buys Highlight GuruFocus.com
Jun-10-19 10:09AM	PolarityTE Shares Rally On Positive Readout From Skin Graft Study In Diabetic Foot Ulcers Benzinga
08:00AM	PolarityTE Announces Final Clinical Data from Pilot Study Showing Closure of Diabetic Foot Ulcers Using SkinTE PR Newswire
Jun-08-19 05:38PM	Ready Trader One: Events, Stocks To Watch At E3 Benzinga
Jun-03-19 08:00AM	PolarityTE Creates Office of the Chief Executive to Focus on Commercialization and Operational Performance PR Newswire
May-31-19 01:33PM	Analysts Recommend These 3 Falling Knives GuruFocus.com
May-21-19 08:00AM	Final Data from Pilot Study on Use of SkinTE for Diabetic Foot Ulcers Accepted as Late-Breaking Abstract at the American Diabetes Association's 79th Scientific Sessions Conference PR Newswire
May-20-19 11:26AM	Implied Volatility Surging for PolarityTE (PTE) Stock Options Zacks -9.79%
May-10-19 09:55AM	3 Small Drug Stocks Poised to Beat Q1 Earnings Estimates Zacks
07:30AM	PolarityTE Announces Clinical Data from Two Studies Showing 12-Week Closure of Difficult-to-Treat Lower Extremity Chronic Wounds Using SkinTE PR Newswire
07:16AM	PolarityTE Reports First Calendar Quarter 2019 Results PR Newswire
May-02-19 09:00AM	Should You Be Concerned About PolarityTE, Inc.'s (NASDAQ:PTE) Historical Volatility? Simply Wall St. +6.72%
May-01-19 08:00AM	PolarityTE to Report Calendar First Quarter Financial Results on May 10, 2019 PR Newswire
Apr-24-19 08:00AM	SkinTE Clinical Data to be Presented, PolarityTE to Host Booth and SkinTE Event at Symposium on Advanced Wound Care (SAWC) Spring, Wound Healing Society Meeting PR Newswire
Apr-10-19 11:00AM	Why PolarityTE Is Sinking Today Motley Fool -10.18%
09:30AM	PolarityTE Announces Pricing of Public Offering of Common Stock PR Newswire
Apr-09-19 04:01PM	PolarityTE Announces Public Offering of Common Stock PR Newswire
Apr-02-19 04:34PM	Lifshitz & Miller LLP Announces Investigation of Bloom Energy Corporation, First Choice Healthcare Solutions, Inc., Nutanix, Inc., PolarityTE, Inc., Revlon, Inc., Tivity Health, Inc., WellCare Health Plans, Inc., and Whitestone REIT PR Newswire
Apr-01-19 08:00AM	PolarityTE Enrolls First Patients in Two Clinical Trials Evaluating SkinTE for the Treatment of Chronic Wounds PR Newswire
Mar-29-19 08:00AM	PolarityTE Announces Richard Hague, Formerly from Sanofi, Genzyme and Recently Anika Therapeutics as Chief Operating Officer PR Newswire
Mar-27-19 08:00AM	Clinical Outcomes Data on SkinTE from Lower Extremity Chronic Wounds to be Presented at Diabetic Limb Salvage (DLS) Conference PR Newswire
Mar-21-19 08:00AM	PolarityTE Hosts Symposium Featuring SkinTE-Treated Burn Survivor, New Clinical Data at American Burn Association Annual Meeting PR Newswire +9.60%
Mar-19-19 05:00PM	PolarityTE to Present at Oppenheimer 29th Annual Healthcare Conference PR Newswire
02:15PM	RM LAW Announces Investigation of PolarityTE, Inc. PR Newswire
01:06PM	Federman & Sherwood Investigates PolarityTE, Inc. for Possible Violations of Federal Securities Laws Business Wire
10:47AM	PolarityTE (PTE) Investigation: Bernstein Liebhard LLP Announces Investigation of PolarityTE, Inc. - PTE GlobeNewswire
Mar-18-19 07:56PM	Bragar Eagel & Squire, P.C. is Investigating PolarityTE, Inc. (PTE) on Behalf of Stockholders and Encourages PTE Investors to Contact the Firm GlobeNewswire -15.64%
05:40PM	PolarityTE (PTE) Investigation: Bernstein Liebhard LLP Announces Investigation Of PolarityTE, Inc. - PTE PR Newswire
04:20PM	Why PolarityTE Stock Tanked Today Motley Fool
02:16PM	Biotech's shares tumble after it says SEC is looking into possible manipulation CNBC
07:00AM	PolarityTE Reports Results and Corporate Update for Two-Month Transition Period Ended December 31, 2018 PR Newswire

PolarityTE, Inc., a biotechnology and regenerative biomaterials company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine and Contract Services. It offers SkinTE, a tissue product for treatment of defects of the skin, as well as contract research services; SkinTE point-of-care device to permit the processing and deployment of SkinTE immediately following the initial harvest at the point-of-car; and PTE 11000, an allogenic, biologically active dressing for use in wound care and aesthetics to accelerate healing of skin. The company also develops OsteoTE, an autologous homologous bone regeneration product; and CartTE, an autologous cartilage regeneration product. In addition, it develops AdipoTE to optimize the delivery of autologous fat; AngioTE for vascular regeneration; NeuralTE for peripheral nerve injuries of the extremities, as well as for patients with neuromas or chronic compression due to joint replacements, migraines, craniofacial injuries, carpal tunnel syndrome, and those who have undergone hernia or abdominal-based procedures; UroTE for the delivery of autologous urogenital epithelium and submucosa; LiverTE to address various causes of liver failure; and BowelTE to deliver an optimized autologous construct to aid in the regeneration of bowel tissue. PolarityTE, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lough Denver	Prior Director and Officer	Nov 01	Option Exercise	0.00	11,111	0	7,181,889	Nov 04 04:05 PM
Seaburg David B	Chief Executive Officer	Oct 19	Sale	1.02	31,032	31,560	919,792	Oct 20 04:05 PM
Hoyler Cameron J.	Gen. Counsel & Exec. VP	Oct 19	Sale	1.03	9,999	10,299	587,438	Oct 20 04:05 PM
Lough Denver	Prior Director and Officer	Oct 01	Option Exercise	0.00	11,111	0	7,174,079	Oct 05 04:05 PM
Seaburg David B	Chief Executive Officer	Sep 30	Sale	1.03	8,514	8,795	950,824	Oct 01 05:29 PM
Hoyler Cameron J.	Gen. Counsel & Exec. VP	Sep 29	Sale	1.01	936	945	597,437	Sep 30 04:05 PM
Hoyler Cameron J.	Gen. Counsel & Exec. VP	Sep 22	Sale	1.02	3,500	3,570	598,373	Sep 23 04:05 PM
Seaburg David B	Chief Executive Officer	Sep 02	Sale	1.13	5,600	6,306	959,338	Sep 04 04:05 PM
Lough Denver	Prior Director and Officer	Sep 01	Option Exercise	0.00	11,111	0	7,166,447	Sep 03 04:05 PM
Dyer Jeffrey Hansen	Director	Aug 24	Sale	1.27	1,000	1,271	53,286	Aug 25 05:00 PM
Hoyler Cameron J.	Gen. Counsel & Exec. VP	Aug 07	Sale	1.53	11,667	17,851	601,873	Aug 10 04:05 PM
Seaburg David B	Chief Executive Officer	Aug 07	Sale	1.53	16,334	24,991	964,938	Aug 10 04:06 PM
Lough Denver	Prior Director and Officer	Aug 03	Option Exercise	0.00	11,111	0	7,158,530	Aug 05 10:56 AM
Lough Denver	Prior Director and Officer	Jul 01	Option Exercise	0.00	11,111	0	7,150,671	Jul 06 11:11 AM
Seaburg David B	Chief Executive Officer	Jul 01	Sale	1.28	8,514	10,881	1,002,451	Jul 02 04:06 PM
Hoyler Cameron J.	Gen. Counsel & Exec. VP	Jun 29	Sale	1.44	936	1,348	622,184	Jun 30 04:05 PM
Lough Denver	Prior Director and Officer	Jun 01	Option Exercise	0.00	11,112	0	7,139,560	Jun 03 11:07 AM
Lough Denver	Prior Director and Officer	May 01	Option Exercise	0.00	11,111	0	7,131,786	May 05 03:21 PM
Lough Denver	Prior Director and Officer	Apr 02	Option Exercise	0.00	11,111	0	7,123,878	Apr 03 11:45 AM
Mann Paul Elliot	Chief Financial Officer	Mar 31	Sale	1.04	23,158	24,084	415,953	Apr 02 04:30 PM
Seaburg David B	Chief Executive Officer	Mar 31	Sale	1.04	21,287	22,138	345,965	Apr 02 04:30 PM
Hoyler Cameron J.	Gen. Counsel & Exec. VP	Mar 30	Sale	1.15	936	1,076	323,120	Mar 31 08:16 PM
Mann Paul Elliot	Chief Financial Officer	Mar 23	Sale	1.05	1,283	1,347	439,111	Mar 25 09:05 PM
Hoyler Cameron J.	Gen. Counsel & Exec. VP	Mar 23	Sale	1.05	3,500	3,675	324,056	Mar 25 09:03 PM
Lough Denver	Prior Director and Officer	Mar 03	Option Exercise	0.00	11,111	0	7,116,001	Mar 04 07:08 PM
Seaburg David B	President	Mar 03	Sale	1.34	5,450	7,303	367,251	Mar 04 04:30 PM
Hague Richard	Chief Operating Officer	Feb 07	Sale	3.02	12,950	39,109	321,895	Feb 07 09:32 PM
Mann Paul Elliot	Chief Financial Officer	Feb 07	Sale	3.02	12,833	38,756	440,393	Feb 07 09:30 PM
Hoyler Cameron J.	Gen. Counsel & Exec. VP	Feb 07	Sale	3.04	11,667	35,468	327,556	Feb 07 09:28 PM
Seaburg David B	President	Feb 07	Sale	3.02	16,333	49,326	372,701	Feb 07 09:26 PM
Lough Denver	Prior Director and Officer	Feb 04	Option Exercise	0.00	11,111	0	7,108,602	Feb 05 10:22 AM
Lough Denver	Prior Director and Officer	Jan 16	Option Exercise	3.12	10,000	31,200	10,000	Jan 21 06:59 PM
Lough Denver	Prior Director and Officer	Jan 16	Sale	4.17	10,000	41,700	0	Jan 21 06:59 PM
Lough Denver	Prior Director and Officer	Jan 03	Option Exercise	0.00	11,111	0	7,097,491	Jan 06 03:01 PM
Mann Paul Elliot	Chief Financial Officer	Dec 23	Sale	2.71	11,000	29,810	453,227	Dec 23 08:12 PM
Erdtmann Rainer M	Director	Dec 16	Sale	2.47	31,846	78,660	30,000	Dec 17 04:30 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience